Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CCT301-38 |
| Synonyms | |
| Therapy Description |
CCT301-38 consists of autologous T cells engineered to express an AXL-targeting chimeric antigen receptor (CAR), which are activated in the tumor microenvironment, potentially resulting in the killing of tumor cells expressing AXL (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CCT301-38 | CCT301 38|CCT30138 CAR-T cells|autologous anti-AXL CAR-T Cells CCT30138 | CCT301-38 consists of autologous T cells engineered to express an AXL-targeting chimeric antigen receptor (CAR), which are activated in the tumor microenvironment, potentially resulting in the killing of tumor cells expressing AXL (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|